Governance

BioPorto is aware of its corporate social responsibility and endeavors to improve social and environmental conditions. In addition, the corporate social responsibility report is provided in BioPorto’s Annual Report. BioPorto has signed the UN Global Compact, and the latest Communication on Progress, which is available here.

Remuneration policy and guidelines for incentive-based remuneration of the board of directors and executive management of BioPorto A/S.

These Guidelines have been prepared pursuant to the Recommendations on Corporate Governance, Recommendation 4 and section 139 of the Danish Companies Act, according to which BioPorto A/S must prepare a remuneration policy and guidelines for incentive remuneration covering the Company’s Board of Directors and Executive Management, where “Executive Management” is defined as the Manager(s) registered with the Danish Business Authority as Manager(s) of the Company.

The Guidelines were approved at the Annual General Meeting of BioPorto A/S on April 29, 2021.

The guidelines are presented for the general meeting’s approval at least every four years and upon significant changes.

Information about the current remuneration of the Company’s Board of Directors and Executive Management is found in the annual report, which is also available on the annual report section of this website.

Remuneration policy and guidelines for incentive-based remuneration.pdf

Vederlagspolitik og retningslinjer for incitamentsaflønning.pdf

BioPorto carries out development and sales activities in the area of diagnostics. Through its activities, the Group is exposed to a number of risks that could significantly affect its operations in the event these risks are not correctly assessed and managed. BioPorto’s policy is to identify and mitigate risks deriving from the Group’s operations and to establish adequate insurance coverage. BioPorto has established risk management as a formalized process for the purpose of generating a close connection between the Group’s ongoing objectives and activities and the individual risk elements within the Group’s sphere of activity. In connection with the new corporate strategy, Management has specifically addressed risks relating to new objectives. Follow this link to learn more: Risk Management

Please click here for BioPorto’s Code of Conduct.

BioPorto  has established a whistleblower scheme covering BioPorto A/S and its subsidiaries. Click here to see the details of our Whistleblower Policy.

BioPorto’s Board Committees are preparatory bodies to assist the Board of Directors in its work and shall provide oversight and monitoring functions over the business.

• Audit Committee
• Nomination & Remuneration Committee
• Clinical & Regulatory Committee

BioPorto is committed to ensuring and furthering equal opportunities for all employees in respect of differences, such as gender, age, religion, sexual orientation and ethnicity, as all, in our view, serve as key components in ensuring a better, more dynamic and healthier business. We believe that employees should be recognized because of, not despite, their diversity. The view extended through this policy also includes maintaining equal opportunities for women and men at all management levels in the BioPorto group. The Board of Directors annually discusses the Company’s activities to ensure relevant diversity at management levels and evaluates the policy on diversity.

BioPorto complies with the European GDPR rules, which gives individuals a number of rights. For more information regarding the use of this site, privacy, and legal/compliance policies, please refer to the following:

• Data Protection Policy
• Data Ethics Policy (PDF)

• Tax Policy
• Quality Policy